F. Stephen Hodi
Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name F. Stephen Hodi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:57 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04356729 · A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic MelanomaF. Stephen Hodi, MD · active not recruiting · Clinical Stage III Cutaneous Melanoma AJCC v8, Stage IV Melanoma, Unresectable Stage III Cutaneous Melanoma · principal investigator
- Ph2NCT03417739 · A Phase II Study of BVD-523 in Metastatic Uveal MelanomaDana-Farber Cancer Institute · terminated · Uveal Melanoma · principal investigator
- Ph1NCT01753089 · Dendritic Cell Activating Scaffold in MelanomaDana-Farber Cancer Institute · completed · Melanoma · principal investigator
- Ph2NCT01551693 · STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV MelanomaDana-Farber Cancer Institute · terminated · Melanoma · principal investigator
- Ph2NCT01495988 · Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant MelanomaMelanoma Research Foundation Breakthrough Consortium · terminated · Melanoma, Metastatic Melanoma · principal investigator
- N/ANCT01489423 · Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without SargramostimEastern Cooperative Oncology Group · completed · Melanoma (Skin) · principal investigator
- Ph2NCT01200238 · STA-9090(Ganetespib) in Metastatic Ocular MelanomaDana-Farber Cancer Institute · completed · Ocular Melanoma · principal investigator
- Ph1NCT01065467 · Panobinostat (LBH589) in Patients With Metastatic MelanomaDana-Farber Cancer Institute · completed · Melanoma, Malignant Melanoma · principal investigator
- Ph1NCT00809588 · Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Stimulating Factor (GMSF)Dana-Farber Cancer Institute · completed · Melanoma · principal investigator
- Ph1NCT00790010 · Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV MelanomaDana-Farber Cancer Institute · completed · Melanoma · principal investigator
- Ph2NCT00788775 · Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged MelanomaDana-Farber Cancer Institute · completed · Mucosal Lentiginous Melanoma, Acral Melanoma, Melanoma · principal investigator
- Ph1NCT00631072 · In Vitro Expanded Autologous Invariant Natural Killer Cells in CancerBeth Israel Deaconess Medical Center · completed · Malignant Melanoma · principal investigator
- Ph2NCT00577382 · SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous MelanomaDana-Farber Cancer Institute · completed · Mucosal Lentiginous Melanoma, Acral Lentiginous Malignant Melanoma · principal investigator
- Ph2NCT00424515 · Imatinib in Patients With Mucosal or Acral/Lentiginous MelanomaDana-Farber Cancer Institute · completed · Mucosal Melanoma, Acral/Lentiginous Melanoma, Chronically Sun Damaged Melanomas · principal investigator
- Ph1NCT00258687 · Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV MelanomaDana-Farber Cancer Institute · completed · Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Renal Cell Carcinoma · principal investigator
- N/ANCT00049010 · Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II MelanomaAlliance for Clinical Trials in Oncology · completed · Melanoma (Skin) · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:57 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 4 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Cancer Immune Monitoring and Analysis CenterU24CA224331 · NCI · DANA-FARBER CANCER INST · fiscal years 2017 to 2026 · $1,934,873 awarded in 2026Same name and institution; not confirmed by an ID
- Program 35: MelanomaP30CA006516 · NCI · DANA-FARBER CANCER INST · fiscal years 2017 to 2026 · $48,198 awarded in 2026Same name and institution; not confirmed by an ID
- Bevacizumab plus Ipilimumab in Unresectable Stage III or Stage IV MelanomaR21CA143832 · NCI · DANA-FARBER CANCER INST · fiscal years 2010 to 2011 · $323,248 awarded in 2011Same name and institution; not confirmed by an ID
- CTLA-4 Blockade in GM-CSF Vaccinated PatientsR21CA105776 · NCI · DANA-FARBER CANCER INST · fiscal years 2003 to 2004 · $364,678 awarded in 2004Same name and institution; not confirmed by an ID
- MELANOMA ANTIGENS INDENTIFIED FROM GMCSF VACCINATIONK08CA078880 · NCI · DANA-FARBER CANCER INST · fiscal years 1998 to 2002 · $87,426 awarded in 2002Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cancer and Leukemia Group BU10CA031946 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Monica M Bertagnolli · fiscal years 1985 to 2013Named on NCT00049010
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:57 UTC. The ranking covers the 200 most relevant of 120 PubMed records, and a shared surname and initials can bring in a namesake. All 120 on PubMed
- Improved survival with ipilimumab in patients with metastatic melanoma.N Engl J Med · 201012,255 citationsRCR 301.1
- Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.N Engl J Med · 201210,484 citationsRCR 282.6
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.N Engl J Med · 20156,463 citationsRCR 203.2
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.Nature · 20144,405 citationsRCR 122.7
- 3,015 citationsRCR 114.3
- 2,979 citationsRCR 97.1
- Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.N Engl J Med · 20132,803 citationsRCR 76.7
- Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.Clin Cancer Res · 20092,575 citationsRCR 56.9
- Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.N Engl J Med · 20152,291 citationsRCR 67.7
- 2,199 citationsRCR 66.5